Takeda Selected by the Dow Jones Sustainability Asia Pacific Index for the 9th Consecutive Year
Takeda Selected by the Dow Jones Sustainability Asia Pacific Index for the 9th Consecutive Year
Osaka, Japan, September 18, 2018 --- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502) announced today that it has been selected for the 9th consecutive year in the Dow Jones Sustainability Asia Pacific Index ("DJSI Asia Pacific"), one of the world’s premier indices for Socially Responsible Investment (SRI)*.
DJSI Asia Pacific, created by S&P Dow Jones Indices LLC (US) and RobecoSAM (CH) is an important indicator for investors considering corporate social responsibility (CSR) performance. Dow Jones assesses and selects leading sustainability-driven companies based on economic, environmental, and social dimensions from questionnaire responses and publicly available company information, including publications from Takeda. Takeda significantly improved its performance in the three dimensions from last year's evaluation, notably the economic dimension by strengthening its product quality and supply chain management. This year, top ranked 150 companies were selected out of 612 companies, including 75 Japanese companies.
As a global pharmaceutical company committed to improving people’s lives, Takeda will continue to pursue its social responsibility to strive towards better health and a brighter future for people worldwide through leading innovation in medicine.
In addition to the DJSI Asia Pacific, Takeda is selected in other benchmark SRI indices as below:
|
Name of |
Company/ |
Country |
Number of |
|
FTSE4Good Developed Index |
FTSE Russell |
UK |
14th consecutive year |
|
Ethibel EXCELLENCE Investment Register |
Forum Ethibel |
BEL |
three times |
|
Prime Status |
ISS-Oekom |
GER |
first time |
|
Global 100 Most Sustainable Corporations in the World Index |
Corporate Knights |
CND |
3rd consecutive year |
* SRI evaluates investments in companies not only in terms of financial performance, but also with an emphasis on corporate social responsibility performance from social, ethical, environmental, and other perspectives.
** A specific group or category of investments that share certain characteristics.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care all over the world.
For more information, visit https://www.takeda.com/newsroom/
About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR commitments, as well as how CSR priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.
Media Contacts:
Japanese Media
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095
Media outside Japan
Tsuyoshi Tada
[email protected]
+1 617 551 2933